Efficacy and safety of high dose accelerated intravenous iron sucrose in patients of iron deficiency anemia
DOI:
https://doi.org/10.18203/2320-6012.ijrms20173157Keywords:
Anemia, Iron sucrose, Iintravenous, Low doseAbstract
Background: Low dose (200 mg) extended Intravenous iron sucrose remains the most common treatment option in patients who are intolerant to oral iron therapy in patients with Iron deficiency anemia (IDA). The objective of this study was to evaluate the efficacy and safety of high dose accelerated intravenous iron sucrose (IS) in the treatment of adults with iron deficiency anemia
Methods: One hundred adult patients with iron deficiency anemia, who had intolerance or showed no effect with oral iron therapy, received daily doses of 500 mg of intravenous iron sucrose until the hemoglobin level was corrected or until receiving the total dose of intravenous iron calculated for each patient.
Results: The mean and median Hb (g/dL) 6.47±1.656 and 6.6 (2) at baseline, 9.61±1.629 and 9.6 (2) at 2 weeks of treatment, 11.85±1.277 and 12 (1) at 4 weeks of treatment respectively. The mean rise of Hb was 3.13±1.41 and 5.37±1.50 after 2 and 4 weeks of treatment respectively (p<0.000). A total of 303 intravenous infusions of iron sucrose were administered and iron sucrose was generally well tolerated with twenty-six patients developing mild and one patient developing moderate adverse drug reactions. There was no serious adverse event recorded.
Conclusions: Accelerated high dose intravenous iron sucrose is a safe and cost effective option minimizing frequent hospital visits in the treatment of adults with iron deficiency anemia who are intolerant or lack satisfactory response to oral iron therapy.
References
World Health Organization Iron deficiency anemia. Assessment, prevention and control. A guide for programme managers. Geneva: WHO; 2001. Available at http://www.who.int/nutrition /publications/en/ida_assessment_prevention_control.pdf. Accessed on 12 January 2010.
World Health Organization The World Health Report 2002: Reducing risks, promoting healthy life. Geneva: World Health Organization: 2002:1-248.
Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008;121(11):943-8.
Cançado RD, Lobo C, Friedrich JR. Tratamento da anemia ferropriva com ferro via oral. Rev Bras Hematol Hemoter. 2010;32(Supl. 2):114-20.
Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy and safety. Hematology Am Soc Hematol Educ Program. 2010:338-47.
Ferrlecit Prescribing Information. Available at http://www.drugs.com/pro/ferlicit. Accessed on 25 June 2017.
Venofer Prescribing Information. Available at http://www.drugs.com/pro/venofer. Accessed on 25 June 2017.
National Institute for Health and Clinical Excellence: Clinical Guideline 39: Anaemia Management in People with Chronic Kidney Disease (CKD), 2006. Available at http://www.guideline.gov/summaries/summary.
Cançado RD, Lobo C, Friedrich JR. Tratamento da anemia ferropriva com ferro via parenteral. Rev Bras Hematol Hemoter. 2010;32(Supl. 2):121-8.
Cançado RD, Figueiredo PO, Olivato MC, Chiattone CS. Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia. Rev Bras Hematol Hemoter. 2011;33(6):439-43.
Blaustein DA, Schwenk MH, Chattopadhyay J, Singh H, Daoui R, Gadh R, et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int Suppl. 2003;(87):S72-7.
Hollands JM, Foote EF, Rodriguez A, Rothschild J, Young S. Safety of high-dose iron sucrose infusion in hospitalized patients with chronic kidney disease. Am J Health Syst Pharm. 2006;63(8):731-4.
Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a randomized, controlled, open-label, multicenter study.Am J Gastroenterol. 2005;100(11):2503-9.
Prasanna B, Naimisha M, Jhansi Ch B, Shaik MV. Safety and efficacy of high dose intravenous iron sucrose for treating anemia in pregnancy. Sch J App Med Sci. 2014;2(2B):623-7.
Vikrant S, Pandey D. Safety and tolerability of high dose intravenous iron sucrose administration in CKD patients - a study from a tertiary care hospital in North India. Indian J Nephrol. 2006;16:129.
